Results

Total Results: 2,080 records

Showing results for "drug".

161. Obesity (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/10_obesity_potential_high_impact_june_2012.pdf
     January 01, 2012 - Naltrexone/bupropion drug is a combination oral, sustained- release drug intended to fight the body's … A new drug application for treating obesity has not been submitted as of this writing. … This drug combination acts on the central nervous system as an appetite suppressant. … Food and Drug Administration (FDA). … FDA accepts new drug application filing for Qnexa. [internet].

162. Evidence Summary CER 208 Treatment For Bipolar Disorder In Adults (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-208-bipolar-evidence-summary.pdf
     August 01, 2018 - their lifetime.6 Of all psychiatric conditions, BD is the most likely to co-occur with alcohol or drug … abuse disorders.7 Purpose of Review To assess the effectiveness of drug and nondrug therapies for … Drug treatments have several purposes. … The publications comprised 67 unique drug studies for acute mania, seven drug studies for depression … We found scattered evidence for some drug interventions that were assessed 3 Table A.

163. Nonopioid Pharmacologic Treatments for Chronic Pain | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/nonopioid-chronic-pain/protocol
     March 01, 2019 - Specific adverse events for each drug class, such as gastrointestinal events, cardiovascular events, … sedation for gabapentin/pregabalin Intermediate outcomes (e.g., pharmacokinetics/pharmacodynamics, drug-drug … Pharmacoepidemiol Drug Saf. 2009;18(12):1166-75. doi: 10.1002/pds.1833. … Pharmacoepidemiology and drug safety. 2009;18(12):1166-75. Higgins J, Green S. … Methods for the Drug Effectiveness Review Project.

164. Nonopioid Pharmacologic Treatments for Chronic Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/nonopioid-pharm-chronic-pain-protocol.pdf
     February 01, 2019 - Specific adverse events for each drug class, such as gastrointestinal events, cardiovascular events, … sedation for gabapentin/pregabalin • Intermediate outcomes (e.g., pharmacokinetics/pharmacodynamics, drug-drug … Pharmacoepidemiol Drug Saf. 2009;18(12):1166-75. doi: 10.1002/pds.1833. PMID: 19718704 7. … Pharmacoepidemiology and drug safety. 2009;18(12):1166-75. 15. Higgins J, Green S. … Methods for the Drug Effectiveness Review Project.

165. Diagnosis and Treatment of Clinical Alzheimer’s-Type Dementia: Evidence Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/Evidence%20Summary_1.pdf
     April 01, 2020 - cognitive impairment; biomarker accuracy for Alzheimer’s disease (AD) in dementia; and effects of CATD drug … Few trials directly compared different drug treatments. … Future BPSD trials also should directly compare drug and nondrug treatment strategies, and drug trials … Food & Drug Administration. U.S. … Food & Drug Administration.

166. Microsoft Word - ehcrr#2toCSI.doc (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/atypical-antipsychotics-seniors-death_research.pdf
     August 01, 2007 - Psychotropic drug use in elderly people with and without dementia. … The quality of antipsychotic drug prescribing in nursing homes. … Food and Drug Administration. … Available at: www.fda.gov/cder/drug/advisory/antipsychotics.ht m. … Paradoxical relations of drug treatment with mortality in older persons.

167. Comparative Effectiveness of Drug Therapy for Psoriatic Arthritis in Adults – An Update to the 2007 Report | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/arthritis-psoriatric/research-protocol
     December 06, 2010 - Review Aug. 17, 2012 Topic Initiated Jul. 3, 2013 Surveillance Report Comparative Effectiveness of Drug … Food and Drug Administration (FDA) to treat patients with PsA are adalimumab, etanercept, golimumab, … The first review did not include certolizumab pegol, golimumab, and tocilizumab drug therapies listed … KQ3: For patients with psoriatic arthritis, do drug therapies differ in harms, tolerability, adherence … KQ4: What are the comparative benefits and harms of drug therapies for psoriatic arthritis in subgroups

168. Obesity (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/10_obesity_potential_high_impact_2012-12-11.pdf
     January 01, 2012 - The drug is classified by the U.S. … Drug Enforcement Administration (DEA) as a Schedule IV drug, which means DEA will review FDA’s recommendation … This drug combination acts on the central nervous system as an appetite suppressant. … FDA approved the drug on July 17, 2012, on the basis of two completed, phase III trials. … Food and Drug Administration (FDA).

169. PULMONARY with "Discussions" in Exec Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - drug- name=orkambi. 14. Walker J. FDA panel backs Vertex cystic-fibrosis drug Orkambi. … drug-name=orkambi http://www.wsj.com/articles/fda-panel-backs-vertex-cystic-fibrosis-drug-orkambi-1431462559 … Policy #DRUG.00080. [internet]. … drug- name=pirfenidone. 71. Medica. … National drug list: drug list - three (3) tier drug plan.

170. A Rapid Evidence Review of Retention Strategies for Medications for Addiction Treatment (MAT) in Adults with Opioid Use Disorder | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/retention-strategies-opioid-use-disorder/rapid-protocol
     May 08, 2019 - Food and Drug Administration approved medications for OUD- methadone, buprenorphine, and extended-release … This rapid review, nominated by the Office of the Assistant Secretary for Health (OASH), Center for Drug … Food and Drug Administration (FDA), the Office of the Assistant Secretary for Mental Health and Substance … the Office of the Assistant Secretary for Planning and Evaluation (ASPE), the National Institute on Drug … Drug and Opioid-Involved Overdose Deaths - United States, 2013- 2017 .

171. Medication-Therapy-Management Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/medication-therapy-management_executive.pdf
     November 01, 2014 - - drug interactions or adverse event � Drug therapy problems that are resolved as defined by primary … studies but typically including the following: needed drug initiated; unnecessary drug discontinued … Gurwitz JH, Rochon P, Food and Drug Administration. … Out-of-Bounds: Rising Prescription Drug Prices for Seniors. … Association of Chain Drug Stores Foundation.

172. S44 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s44.pdf
     October 01, 2007 - ARTICLE Designed Delays Versus Rigorous Pragmatic Trials Lower Carat Gold Standards Can Produce Relevant Drug … We simplified the PRT strategy by using designed delays (DD) to evaluate drug policies. … covering the elderly, the poor, and families with high drug expenditures, introduced a drug benefit … Periodic letters on evidence- based drug therapy improves prescribing: a randomized trial. … Randomized controlled trial of a drug policy change by British Columbia PharmaCare.

173. PULMONARY with "Discussions" in Exec Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1312.pdf
     December 01, 2013 - -based, online aggregator of prescription drug prices listed prices for the drug at about $27,000 per … Available: http://www.vrtx.com/current-projects/drug- candidates/vx-770.html. … Food and Drug Administration (FDA); 2012 Jan 31 [accessed 2012 Feb 22]. [2 p]. … Drug coverage guidelines. [internet]. … Food and Drug Administration (FDA); [accessed 2012 Jun 28]. [2 p].

174. Antipsychotics for the Prevention and Treatment of Delirium: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/delirium-research-protocol.pdf
     June 01, 2018 - Currently, there are no medications approved by the Food and Drug Administration for the prevention … antipsychotic drugs cannot be isolated. 7 Comparison • For KQ 1, we will include non-drug … • For KQ 2, we will include non-drug approaches to treating delirium, including placebo, active … Non-drug interventions will be categorized following the scheme developed by Oh and colleagues.19 … Does antipsychotic drug use increase the risk of long term mortality?

175. Who Uses Exenatide For Glucose Control in Diabetes Mellitus? A Retrospective Cohort Study of a New Therapy | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/diabetes-glucose-control/research
     August 04, 2010 - Health, Department of Epidemiology Abstract Background: Exenatide was approved by the Food and Drug … We evaluated whether early use of this drug was consistent with the FDA-approved indications for use. … The dataset included patients with a diagnosis of DM, or a claim for a drug used to treat DM, between … (San Diego, CA), was approved by the FDA on April 28, 2005. 2 Exenatide is a first-in-class drug that … , he was considered to have been on this drug for that interval.

176. Obesity (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/obesity_hi_impact.pdf
     April 17, 2012 - Naltrexone/bupropion combination drug is an oral, sustained-release drug intended to fight the body's … Food and Drug Administration (FDA). … Pharmaceutical companies struggle to develop a drug to treat obesity. … Lorcaserin: FDA issues complete response letter for Lorcaserin new drug application. … FDA accepts new drug application filing for Qnexa. [internet].

177. Migraine Protocol-Appendix 20111103 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/migraine_protocol-appendix_20111103.pdf
     November 03, 2011 - Pharmacological classes for migraine prevention Drug, ATC Code* Class of Drug ANTIEPILEPTICS … (continued) Source: www.effectivehealthcare.ahrq.gov Published Online: November 3, 2011 A-2 Drug … (continued) Source: www.effectivehealthcare.ahrq.gov Published Online: November 3, 2011 A-3 Drug … drug management.mp. 2. exp patient care team/ 3. exp delivery of health care, integrated/ 4. … drug surveillance.mp. 10. exp drug monitoring/ 11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10

178. S143 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s143.pdf
     October 01, 2007 - Chief among them is the indication for the drug—a patient must have the condition for which the drug … In a randomized drug trial, the allocation of subjects to treatment and control groups at random leads … Seeger, PharmD, DrPH, Ingenix i3 Drug Safety, 950 Winter Street, Suite 3800, Waltham, MA 02451. … by a text search for the drug name. … Drug treatment of lipid disorders. N Engl J Med. 1999;341: 498–511. 6.

179. Dietary-Supplements Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/dietary-supplements_surveillance.pdf
     January 01, 2013 - Tufts University Boston, MA Katharine Lillie, MD Center for Drug Evaluation & Research, Food & Drug … Intermediate cardiovascular efficacy outcomes of cardiovascular drug(s) plus supplement versus drug(s … (drug-drug interactions) In August 2012, FDA reported an association between Lovaza and recurrent … Clinical or intermediate harms with cardiovascular drug(s) plus supplement versus drug(s) plus placebo … Pharmacokinetic outcomes with cardiovascular drug(s) plus supplement versus drug(s) plus placebo, no

180. PULMONARY with "Discussions" in Exec Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1506.pdf
     October 01, 2015 - Available: http://www.vrtx.com/current-projects/drug- candidates/vx-770.html. … Vertex's two-drug cystic fibrosis treatment shows promise. [internet]. … FDA panel backs Vertex cystic-fibrosis drug Orkambi. Wall Str J. 2015 May 12. … National drug list: drug list - three (3) tier drug plan. … HealthPartners PreferredRx: preferred drug list (formulary). [internet].